
|Videos|November 6, 2020
Recent Developments in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Author(s)Matthew J. Frigault, MD
Matthew J. Frigault, MD, reviews the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma and real-world data supporting it's use.
Advertisement
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
2
Crawford Strunk, MD, on the Importance of Palliative Care in Sickle Cell Disease
3
The Importance of Palliative Care in Sickle Cell Disease
4
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
5











































